Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market, by Product Type (Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, and Scoring Balloon Catheter), by Balloon Material (Polyolefin copolymer (POC), Polyethylene (PE), and Polyethylene terephthalate (PET)), by End User (Hospitals and Ambulatory Surgical Centers) by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2.2 billion in 2022 and expected to exhibit a CAGR of 8% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing on receiving product approvals from regulatory authorities, and this is expected to drive the market growth over the forecast period.
For instance, in July 2021, Medtronic plc, a medical device company, announced the launch of Prevail drug-coated balloon (DCB) catheter in Europe.
Moreover, in November 2020, Shanghai MicroPort Medical (Group) Co., Ltd., an international medical device company, received marketing approval from the Regulatory, Control and Surveillance National Agency of Ecuador for its proprietary products such as Firehawk Rapamycin Target Eluting Coronary Stent System (Firehawk), Firebird2 Coronary Rapamycin-Eluting CoCr Stent System (Firebird2), Firefighter PTCA Balloon Catheter (Firefighter), and FOXTROT NC PTCA Balloon Catheter (FOXTROT NC).
Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 583,038,110 cases of coronavirus disease (COVID-19) were reported till August 9, 2022, across the globe.
Moreover, according to the data published in healthcare in Europe in 2020, in Europe, the British Heart Foundation had monitored the COVID-19 situation and found that around 371,000 heart operations and procedures were performed in 2020, which decreased 22% as compared to that in 2019, i.e. 473,000 procedure were carried out.
Browse 53 Market Data Tables and 38 Figures spread through 154 Pages and in-depth TOC on “Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market” - Global Forecast to 2030, by Product Type (Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, and Scoring Balloon Catheter), by Balloon Material (Polyolefin copolymer (POC), Polyethylene (PE), and Polyethylene terephthalate (PET)), by End User (Hospitals and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market, click the link below:
Key players operating in the market are focusing on the adoption of inorganic growth strategies such as mergers, collaborations, partnerships, and acquisitions, in order to strengthen their position in the global market. For instance, in March 2021, B. Braun Interventional Systems (BIS), a medical device company, announced a collaboration with Infraredx, a medical equipment manufacturing company, for the trial of B. Braun SeQuent Please ReX. The companies collaborated to accelerate the FDA investigational device exemption (IDE) clinical trial for SeQuent Please ReX drug-coated PTCA balloon catheter, which received breakthrough device designation in 2019.
Key Takeaways of the Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market:
- The global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market is expected to exhibit a CAGR of 8% over the forecast period, owing to rising product launches and approvals. For instance, in January 2022, Cardiovascular Systems, Inc., a medical device company, along with OrbusNeich Medical Company Ltd, a manufacturer of catheters, announced the U.S Food and Drug Administration premarket (PMA) approval of OrbusNeich’s Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter (Scoreflex NC).
- Among product type, the normal balloon catheter segment is expected to account for the largest market share during the forecast period, owing to rising research and development activities and product launches by market players. For instance, in April 2021, Cardiovascular Systems Inc. a medical device company which develops systems for the treatment of peripheral and coronary artery disease, has launched the full line of JADE percutaneous transluminal angioplasty over-the-wire (OTW) balloon catheters in the U.S.
- Key players operating in the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market include Cook Group, Medtronic Plc., Becton, Dickinson and Company, Abbott, Koninklijke Philips N.V., ENDOCOR GmbH, Cardinal Health, NIPRO, Terumo Corporation, Boston Scientific Corporation, Surmodics, Inc., Teleflex Incorporated, BIOTRONIK SE & Co. KG, Biomerics, Shockwave Medical Inc., Microport Scientific Corporation, Nordson Corporation, and S3V Vascular Technologies Pvt. Ltd.
